ASN
VRDN icon

Advisory Services Network’s Viridian Therapeutics VRDN Stock Holding History

Advisory Services Network’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$879K Buy
47,860
+47,760
+47,760% +$770K 0.01% 1086
2026
Q1 		$1.96K Buy
+100
New +$2.97K ﹤0.01% 4142

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Advisory Services Network's VRDN Position: Q2 2026 in Review

Advisory Services Network increased its Viridian Therapeutics (VRDN) stake by 47,760% in Q2 2026, buying an estimated $770K and bringing the position to 47,860 shares worth $879K. The position accounts for 0.01% of the portfolio, ranked #1086.

Advisory Services Network first reported a position in VRDN in Q1 2026 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Advisory Services Network held 47,860 shares of Viridian Therapeutics worth $879K as of Q2 2026.
  • Advisory Services Network bought 47,760 Viridian Therapeutics shares in Q2 2026, an estimated $770K.
  • Viridian Therapeutics made up 0.01% of Advisory Services Network's portfolio in Q2 2026, its #1086 holding.
  • Advisory Services Network first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.